Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025

High Triple-Digit Million-Euro Sales Forecasted From 2024

 
• By Dean Rudge
  
Fresenius Kabi
Adalimumab, pegfilgrastim and tocilizumab are three of the five biosimilar products disclosed by Fresenius Kabi. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products